Pneumologie 2024; 78(S 01): S77
DOI: 10.1055/s-0044-1778903
Abstracts
Interstitielle und seltene Lungenerkrankungen

Krebs von den Lungen-6 as a potential predictive biomarker in fibrosing interstitial lung diseases

C Lederer
1   Zentrum für Interstitielle und Seltene Lungenerkrankungen, Pneumologie und Beatmungsmedizin, Thoraxklinik Heidelberg, Universitätsklinikum Heidelberg; Translationales Zentrum für Lungenforschung Heidelberg (Tlrc), Mitglied des Deutschen Zentrums für Lungenforschung (Dzl)
,
K Mayer
2   Zentrum für Interstitielle und Seltene Lungenerkrankungen, Pneumologie und Beatmungsmedizin, Thoraxklinik Heidelberg, Universitätsklinikum Heidelberg
,
V Somogyi
3   Klinik für Pneumologie, Zentrum für Thoraxerkrankungen, Universitätsmedizin Mainz, Lungenzentrum Mainz
,
K Kriegsmann
4   Universitätsklinikum Heidelberg; Laborarztpraxis Rhein-Main Mvz; Hämatologie, Onkologie und Rheumatologie
,
M Kriegsmann
5   Universitätsklinikum Heidelberg; Pathologie
,
K Buschulte
6   Pneumologie und Beatmungsmedizin, Thoraxklinik am Universitätsklinikum Heidelberg; Sektion für Translationale Forschung, Thoraxklinik am Universitätsklinikum Heidelberg; Translational Lung Research Center (Tlrc) Heidelberg, Member of the German Center for Lung Research (Dzl), Germany, Heidelberg; Thoraxklinik am Universitätsklinikum Heidelberg
,
M Polke
7   Zentrum für Interstitielle und Seltene Lungenerkrankungen, Pneumologie und Beatmungsmedizin, Thoraxklinik, Universitätsklinikum Heidelberg, Heidelberg; Translational Lung Research Center (Tlrc) Heidelberg, Member of the German Center for Lung Research (Dzl), Heidelberg
,
P Findeisen
8   Mvz Labor Dr. Limbach Kollegen, Heidelberg
,
F Herth
9   University Hospital Heidelberg; Institute of Internal Medicin III – Pneumology; Thoraxklinik
,
M Kreuter
10   Universitätsklinikum Mainz; Klinik für Pneumologie, Beatmungs- und Schlafmedizin, Marienhaus Klinikum Mainz, Klinik für Pneumologie, Zentrum für Thoraxerkrankungen, Universitätsmedizin Mainz; Pneumologie
› Author Affiliations
› Further Information
Also available ateRef
 
 

    Background As fibrosing interstitial lung diseases (fILDs) are associated with high mortality, monitoring of disease activity under treatment is highly relevant. Krebs von den Lungen-6 (KL-6) is associated with the presence and severity of different fILDs, mainly in Asian patient populations.

    Objectives Our aim was to evaluate KL-6 as a predictive biomarker in fILDs in Caucasian patients.

    Methods Consecutive patients with fILDs were recruited prospectively and serum concentrations of KL-6 were measured at baseline (BL), after 6 and 12 months (6 Months, 12 Months). Clinical characteristics including pulmonary function tests were assessed at 6-monthly visits and correlated with KL-6 BL levels as well as with KL-6 level changes.

    Zoom
    Fig. 1 Correlation of absolute KL-6 levels at 6 months and 12 months and KL-6 level change with (A) FVC and B) DLCOSB. Abbreviations: FVC=forced vital capacity in% of predicted normal value, DLCOSB=diffusion capacity of the lungs for carbon monoxide in% of predicted normal value.

    Results A total of 47 fILD patients were included (mean age: 65 years, 68% male). KL-6 levels at BL were significantly higher in fILD patients than in healthy controls (n= 44, mean age: 45, 23% male) (ILD: 1,757± 1960 U/mL vs. control: 265± 107 U/mL, p< 0.0001). However, no differences were noted between ILD subgroups. KL-6 decreased significantly under therapy (6MΔBL-KL6:−486± 1,505 mean U/mL, p= 0.032; 12MΔBLKL6:−547± 1,782 mean U/mL, p= 0.041) and KL-6 level changes were negatively correlated with changes in pulmonary function parameters (forced vital capacity [FVC]: r=−0.562, p< 0.0001; DLCOSB: r=−0.405, p= 0.013). While neither absolute KL-6 levels at BL nor KL-6 level changes were associated with ILD progression (FVC decline≥10%, DLCOSB decline≥15% or death), patients with a stable FVC showed significantly decreasing KL-6 levels (p= 0.022).

    Conclusions A decline of KL-6 under therapy correlated with a clinically relevant stabilization of lung function. Thus, KL-6 might serve as a predictive biomarker, which however must be determined by larger prospective cohorts.


     

    Publication History

    Article published online:
    01 March 2024

    © 2024. Thieme. All rights reserved.

    Georg Thieme Verlag
    Rüdigerstraße 14, 70469 Stuttgart, Germany

     
    Zoom
    Fig. 1 Correlation of absolute KL-6 levels at 6 months and 12 months and KL-6 level change with (A) FVC and B) DLCOSB. Abbreviations: FVC=forced vital capacity in% of predicted normal value, DLCOSB=diffusion capacity of the lungs for carbon monoxide in% of predicted normal value.